Should I buy or sell Pyxis Oncology stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PYXS shares. View PYXS analyst ratings or view top-rated stocks .

What is Pyxis Oncology's stock price target for 2024?

7 brokerages have issued 1 year price targets for Pyxis Oncology's shares. Their PYXS share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price. View analysts price targets for PYXS or view top-rated stocks among Wall Street analysts .

How have PYXS shares performed in 2024?

Pyxis Oncology's stock was trading at $1.80 at the start of the year. Since then, PYXS shares have increased by 151.7% and is now trading at $4.53. View the best growth stocks for 2024 here .

Are investors shorting Pyxis Oncology?

Pyxis Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,700,000 shares, an increase of 65.6% from the March 15th total of 1,630,000 shares. Based on an average daily volume of 875,100 shares, the short-interest ratio is currently 3.1 days. Approximately 6.9% of the shares of the company are sold short. View Pyxis Oncology's Short Interest .

When is Pyxis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PYXS earnings forecast .

How were Pyxis Oncology's earnings last quarter?

Pyxis Oncology, Inc. (NASDAQ:PYXS) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.16.

When did Pyxis Oncology IPO?

Pyxis Oncology (PYXS) raised $158 million in an IPO on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.

How do I buy shares of Pyxis Oncology?

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PYXS

Pyxis Oncology (PYXS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PYXS Stock Alerts

$4.53

-0.30 (-6.21%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.28
▼
$4.86
50-Day Range: $3.65
▼
$6.59
52-Week Range: $1.35
▼
$6.85

Volume: 467,801 shs
Average Volume: 811,849 shs
Market Capitalization: $263.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Get Pyxis Oncology alerts:

Pyxis Oncology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 87.6% Upside
$8.50 Price Target
Short Interest: Bearish
6.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.85) to ($1.30) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.72 out of 5 stars

Medical Sector

623rd out of 919 stocks

Pharmaceutical Preparations Industry

265th out of 405 stocks

4.5

Analyst's Opinion

Consensus Rating
Pyxis Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Pyxis Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
6.93% of the float of Pyxis Oncology has been sold short.
Short Interest Ratio / Days to Cover
Pyxis Oncology has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pyxis Oncology has recently increased by 65.64%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Pyxis Oncology does not currently pay a dividend.
Dividend Growth
Pyxis Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PYXS.

1.9

News and Social Media Coverage

News Sentiment
Pyxis Oncology has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Pyxis Oncology this week, compared to 1 article on an average week.
Search Interest
Only 11 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.40% of the stock of Pyxis Oncology is held by insiders.
Percentage Held by Institutions
Only 39.09% of the stock of Pyxis Oncology is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Pyxis Oncology are expected to decrease in the coming year, from ($0.85) to ($1.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pyxis Oncology is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pyxis Oncology is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pyxis Oncology has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Pyxis Oncology Stock (NASDAQ:PYXS)

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

PYXS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PYXS Stock News Headlines

April 14, 2024 | finance.yahoo.com

PYXS Oct 2024 10.000 call

April 12, 2024 | americanbankingnews.com

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Reaffirmed by HC Wainwright

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

April 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Pyxis Oncology as PYX-201 Showcases Promising Preclinical Data and Broad Therapeutic Potential

April 3, 2024 | msn.com

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

March 28, 2024 | globenewswire.com

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 28, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)

March 28, 2024 | seekingalpha.com

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

March 27, 2024 | investorplace.com

3 Biotech Stocks to Buy on the Dip: March 2024

March 27, 2024 | msn.com

Pyxis Oncology gets $8M payment for sale pf royalty rights

March 27, 2024 | globenewswire.com

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

March 25, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Pyxis Oncology’s PYX-201 Based on Strong Safety Profile and Promising Therapeutic Potential

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Pyxis Oncology on Strong Clinical and Financial Prospects

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Pyxis Oncology’s Financial Health and Promising Drug Candidate PYX-201 Bolster Optimism

March 21, 2024 | marketwatch.com

Pyxis Oncology Shares Fall 10% After Apparent Delay in Results

March 21, 2024 | investorplace.com

PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023

March 21, 2024 | benzinga.com

Pyxis Oncology: Q4 Earnings Insights

March 21, 2024 | finance.yahoo.com

Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges

March 21, 2024 | globenewswire.com

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

March 19, 2024 | investorplace.com

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

March 19, 2024 | markets.businessinsider.com

Pyxis Oncology (PYXS) Receives a Buy from Leerink Partners

March 17, 2024 | finance.yahoo.com

PYXS Apr 2024 10.000 call

March 17, 2024 | finance.yahoo.com

PYXS Apr 2024 7.500 put

March 15, 2024 | finance.yahoo.com

PYXS Jul 2024 7.500 call

March 13, 2024 | globenewswire.com

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

March 7, 2024 | globenewswire.com

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

See More Headlines

Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PYXS
CUSIP: N/A
CIK: 1782223
Web: www.pyxisoncology.com
Phone: 617-221-9059
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $12.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +91.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -52.60%
Return on Assets: -41.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.84
Quick Ratio: 4.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.81 per share
Price / Book: 1.58

Miscellaneous

Outstanding Shares: 58,133,000
Free Float: 53,250,000
Market Cap: $258.69 million
Optionable: Optionable
Beta: 1.51

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. John L. Flavin M.B.A. (Age 53)
MBA, Ph.D., Co-Founder & Independent Chairman
Comp: $87.5k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PYXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pyxis Oncology stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PYXS shares.
View PYXS analyst ratings or view top-rated stocks.
What is Pyxis Oncology's stock price target for 2024?: 7 brokerages have issued 1 year price targets for Pyxis Oncology's shares. Their PYXS share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price.
View analysts price targets for PYXS or view top-rated stocks among Wall Street analysts.
How have PYXS shares performed in 2024?: Pyxis Oncology's stock was trading at $1.80 at the start of the year. Since then, PYXS shares have increased by 151.7% and is now trading at $4.53.
View the best growth stocks for 2024 here.
Are investors shorting Pyxis Oncology?: Pyxis Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,700,000 shares, an increase of 65.6% from the March 15th total of 1,630,000 shares. Based on an average daily volume of 875,100 shares, the short-interest ratio is currently 3.1 days. Approximately 6.9% of the shares of the company are sold short.
View Pyxis Oncology's Short Interest.

When is Pyxis Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PYXS earnings forecast.
How were Pyxis Oncology's earnings last quarter?: Pyxis Oncology, Inc. (NASDAQ:PYXS) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.16.
When did Pyxis Oncology IPO?: Pyxis Oncology (PYXS) raised $158 million in an IPO on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.
How do I buy shares of Pyxis Oncology?: Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYXS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial